Palani Santhosh 4

What Happened Palani Santhosh, a director of Pyxis Oncology, received a grant of 45,867 derivative shares on 2026-03-24. The award was reported as acquired at $0.00 (no cash paid). According to the filing footnote, the shares will vest 100% on the first anniversary of the grant, subject to continued service.

Key Details

• Transaction date: 2026-03-24; filing date: 2026-03-25 (appears timely).
• Grant type/code: Award/Acquisition (derivative shares) reported at $0.00 per share; total reported value $0.
• Vesting: 100% vests on the first anniversary of the grant, contingent on continued service (per footnote).
• Shares owned after transaction: total beneficial ownership not specified in the provided summary—see the Form 4 for full holdings.
• No indication of a 10b5-1 plan, tax withholding, or a cashless exercise in this filing.

Context This was a time‑based equity award (derivative/option-like or RSU-style grant) meant for retention and alignment; it does not represent an immediate open‑market purchase or sale. Such awards typically indicate compensation rather than a direct market signal; the shares are subject to vesting and are not freely tradable until vesting conditions are met.